Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer;Quimioterapia em câncer de pulmão não pequenas células metastático estádio IV: Além da primeira linha

Revista da Associacao Medica Brasileira

Volumn 57, Issue 6, 2011, Pages 686-691

  Younes, Riad Naim ^a   Pereira, José Rodrigues ^b   Fares, Abdo Latif ^c   Gross, Jefferson Luiz ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ISCMSP   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Antineoplastic combined chemotherapy protocols; Carcinoma; Drug therapy; Lung neoplasms; Neoplasm metastasis; Non small cell lung

Indexed keywords

EID: 84855984151     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302011000600017     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. Erratum in: CA Cancer J Clin. 2011;61(2):133-4.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. Erratum in: CA Cancer J Clin. 2011;61(2):134.
3. Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2010: incidência de câncer no Brasil. [cited on 15 May 2011]. Rio de Janeiro: INCA, 2009. Available from: http://www.inca.gov.br/estimativa/2010/.
4. Younes RN, Schutz FA, Gross JL. Preoperative and pathological staging of NSCLC: retrospective analysis of 291 cases. Rev Assoc Med Bras. 2010;56(2):237-41.
5. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol 2007;26(1):60-5.
6. Suehisa H, Toyooka S. Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama. 2009;63(5):223-30.
7. Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a Randomized Study of Early Palliative Care. J Clin Oncol. 2011;29(17):2319-26.
8. Sun HB, Wang SY, Ou W, Zhang BB, Yang H, Fang Q. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Lung Cancer. 2010;68(3):403-8.
9. Tibaldi C, Mazzoni E, Arcabasso G, Dincecco A, Antonuzzo A, Menconi G, et al. Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. Clin Lung Cancer. 2009;10(1):53-7.
10. Shepherd FA, Abratt R, Crino L, Green M, Sandler A, Steward W, et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer. 2000;30(2):117-25.
11. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97.
12. Moro-Sibilot D, Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, et al. Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin. 2010;26(11):2661-72.
13. Owonikoko TK, Ramalingam SS, Belani CP. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res. 2010;16(9):2496-504.
14. Cafarotti S, Leuzzi G, Lococo F, Congedo MT. Mortality, morbidity and late survival in lung resection for non-small cell lung cancer in the elderly population. Interact Cardiovasc Thorac Surg. 2011;12(5):753.
15. Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11(10):1095-9.
16. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapyi n patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31.
17. Guida C, Maione P, Rossi A, Bareschino M, Schettino C, Barzaghi D, et al. Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development. Crit Rev Oncol Hematol. 2008;68(3):222-32.
18. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(11):1836-43.
19. Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer. 2011;74(1):89-97.
20. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer. 2011; May 10. [Epub ahead of print]
21. Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010;15(12):1344-51.
22. De Marinis F, De Santis S, De Petris L. Second-line chemotherapy for non-small cell lung cancer. Ann Oncol. 2006;17(Suppl 5):68-71.
23. Belani CP, Eckardt J. Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004;46(Suppl 2):S3-11.
24. Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, et al. Rationale for treatment and study design of TAILOR: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer. 2011;12(2):138-41.
25. Ibrahim EM, Abouelkhair KM, Al-Masri OA, Chaudry NC, Kazkaz GA. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung. 2011;189(3):193-8.
26. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous or switch strategy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Chest. 2011;140(1):117-26.
27. Naime FF, Younes RN, Kersten BG, Anelli A, Beato CA, Andrade RM, et al. Metastatic non-small cell lung cancer in Brazil: treatment heterogeneity in routine clinical practice. Clinics. 2007;62(4):397-404.
28. Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712-9.
29. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer. 2010;46(4):735-43.
30. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011 May 10. [Epub ahead of print]
31. Qian Q, Zhan P, Yu L, Shi Y, Cheng J, Wei S, et al. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during hemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer. Clin Lung Cancer. 2011;12(2):131-7.
32. Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer. 2011;12(2):106-15.